Complete ENSC Stock Valuation Analysis
Comprehensive intrinsic value analysis using 2 different methodologies
ENSC DCF Analysis
ENSC (Ensysce Biosciences, Inc.) discounted cash flow analysis with multiple scenarios, growth assumptions, and terminal value calculations
Financial Projections
| Metrics | 2022 (Historical) | 2023 (Historical) | 2024 (Historical) | 2025 (Projected) | 2026 (Projected) | 2027 (Projected) | 2028 (Projected) | 2029 (Projected) |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5M | $2.2M | $5.2M | $6.5M | $8.1M | $10.2M | $12.7M | $15.9M |
| Revenue Growth % | - | -11.6% | 133.6% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% |
| EBIT | $-24.2M | $-10.7M | $-6730.1B | $325.6K | $407.0K | $508.8K | $636.0K | $795.0K |
| EBIT Margin % | -959.9% | -480.5% | -129176467.5% | 5.0% | 5.0% | 5.0% | 5.0% | 5.0% |
| Tax Rate % | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% |
| NOPAT | $-18.2M | $-8.0M | $-5047.6B | $244.2K | $305.3K | $381.6K | $477.0K | $596.2K |
| NOPAT Margin % | -719.9% | -360.4% | -96882350.6% | 3.8% | 3.8% | 3.8% | 3.8% | 3.8% |
| Capex | $0 | $2 | $0 | $65.1K | $81.4K | $101.8K | $127.2K | $159.0K |
| Capex / Revenue % | 0.0% | 0.0% | 0.0% | 1.0% | 1.0% | 1.0% | 1.0% | 1.0% |
| Depreciation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| D&A / Revenue % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Change in NWC | $-3.3M | $3.1M | $4.2M | $0 | $0 | $0 | $0 | $0 |
| NWC Change / Revenue % | -132.6% | 139.9% | 80.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Unlevered FCF | $-14.8M | $-11.2M | $-5047.6B | $179.1K | $223.9K | $279.8K | $349.8K | $437.2K |
| UFCF % Chg. | - | 24.7% | -45231005.5% | 100.0% | 25.0% | 25.0% | 25.0% | 25.0% |
| FCF / Revenue % | -587.3% | -500.3% | -96882430.9% | 2.7% | 2.8% | 2.8% | 2.8% | 2.8% |
| Discount Factor | - | - | - | 0.923 | 0.852 | 0.786 | 0.726 | 0.670 |
| Present Value of FCF | - | - | - | $165.3K | $190.7K | $220.1K | $253.9K | $292.9K |
| Sum of PV of UFCF | - | - | - | $165.3K | $356.0K | $576.1K | $830.0K | $1.1M |
WACC Calculation
Weighted Average Cost of Capital used for discounting cash flows.
| WACC Calculation | Value |
|---|---|
| Cost of Debt | 6.8% |
| Tax Rate | 25.0% |
| After Tax Cost of Debt | 5.1% |
| Risk Free Rate | 4.29% |
| Market Risk Premium | 4.3% |
| Beta | 0.98 |
| Cost of Equity | 8.5% |
| Total Debt | $301.7K |
| Market Cap | $5.3M |
| Total Capital | $5.6M |
| Debt Weighting | 5.4% |
| Equity Weighting | 94.6% |
| WACC | 8.3% |
Terminal Value
Choose between perpetuity growth or exit multiple methods.
| Terminal Value Calculation | Value |
|---|---|
| Terminal Growth Rate | 2.5% |
| Final Year FCF | $437.2K |
| Terminal Value | $7.7M |
| PV of Terminal Value | $5.1M |
| Cumulative PV of UFCF | $1.1M |
| Net Debt | $-3.2M |
| Equity Value | $9.5M |
| Shares Outstanding | 1.7M |
| Implied Share Price | $5 |
| Current Share Price | $2 |
| Implied Upside/(Downside) | +141.9% |
Valuation Summary
$5.42
Implied Price
$2.24
Current Price
+141.9%
Upside/Downside
8.3%
WACC
ENSC Peer Valuation Analysis
Relative valuation based on comparable company trading multiples
Peer Valuation Analysis
Fair Value Range Analysis
Based on median multiples from 7 peer companies in Healthcare
P/E Ratio
$0.00
-100.0%
Peer Median: 0.0x
EV/EBITDA
$0.00
-100.0%
Peer Median: 0.0x
P/S Ratio
$2.24
+0.0%
Peer Median: 3.6x
Interpretation: Each multiple provides a different perspective on fair value. Consider which multiple is most relevant for ENSC's business model and current situation.
Multiple Comparison
| Multiple | ENSC Current | Peer Median | Peer Average | Premium/Discount | Assessment |
|---|---|---|---|---|---|
| P/E Ratio | -0.5x | 0.0x | 0.0x | -Infinity% | Undervalued |
| EV/EBITDA | Infinityx | 0.0x | 0.0x | Infinity% | Overvalued |
| P/S Ratio | 3.6x | 3.6x | 3.6x | 0.0% | Fair Value |
Peer Companies
Click any company to view their valuation
| Company | Market Cap | P/E Ratio | EV/EBITDA | P/S Ratio |
|---|---|---|---|---|
| $0.00B | 0.0x | 0.0x | 0.0x | |
| $0.01B | 0.0x | 0.0x | 0.0x | |
| $0.01B | 0.0x | 0.0x | 0.0x | |
| $0.00B | 0.0x | 0.0x | 0.0x | |
| $0.01B | 0.0x | 0.0x | 3.6x | |
| $0.01B | 0.0x | 0.0x | 494.9x | |
| $0.01B | 0.0x | 0.0x | 0.0x |